Category: therapeutics

Mesenchymal stem cells isolated from human umbilical cord (hMSCs) are modified for the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease).

Category(s):
Subcategory(s):

The technology presents a novel structural modification of an existing first generation Grp94 selective inhibitor to generate a second generation Grp94-specific scaffold which has greater affinity and selectivity compared to existing inhibitors and prevents unfavorable binding of other Hsp90 isoforms.

Category(s):

Unique chemical derivatives invented by University of Kansas (KU) researchers that could be used to detect inhibitors of cellular efflux transporters and other agents. 

Category(s):

This invention presents a novel series of modified cephalosporins, which exclusively target non-replicating mycobacterium tuberculosis.

Category(s):
Subcategory(s):

Novel ligands designed to activate mu opioid receptors and provide analgesic effects without opioid-related side effects, providing specific insight into the cellular impact of opioid receptor-based activation as related to pain medications.  These ligands could be used as a tool to negate drug tolerance and dependence as well as other adverse side effects.

Photo-mediated Ultrasound Therapy (PUT) is a non-pharmacological, highly targeted, non-invasive treatment which selectively disrupts the microvasculature (arteries or veins independently) without catheterization/injection or damage to the surrounding tissue.

Category(s):
Subcategory(s):

The invention relates to protecting against Salmonella-type pathogens and more particularly, compositions and methods for immunizing against infection by typhoidal and non-typhoidal Salmonella serovars.

Category(s):

The invention consists of compounds for the treatment of parasitic diseases such as Trypanosomiasis and Leishmaniasis.  Compounds are first-in-class, and selectively targeted towards pathogenic cells with nanomolar potency.

Category(s):
Subcategory(s):

This invention describes the first selective inhibitor of heat shock protein 90 kDa beta (Hsp90β). The invented inhibitor selectively binds to the N-terminus of Hsp90β and may be developed for the treatment of cancers. The inhibitor was developed based on the sequence alignment of the N-terminal ATP-binding domains of Hsp90α and Hsp90β complexed with a non-selective Hsp90 inhibitor, which revealed Hsp90β-specific residues that were key to exploit the selectivity of the new inhibitor. 

Category(s):
Subcategory(s):

Structural modification of a non-selective aminocyclohexanol-based heat shock protein 90 KDa (Hsp90) inhibitor led to a highly selective inhibitor of glucose regulated protein 94 kDa (Grp94). The new Grp94-selective inhibitor can be used to develop an effective therapy for the treatment of metastatic cancer and/or primary open angle glaucoma (POAG).

Category(s):
Subcategory(s):

Pages


Events
KU Today